FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Empliciti Combo Prolongs Survival in Difficult-to-Treat Multiple Myeloma, New Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a regimen including Pomalyst…
Selinexor Combo Yields Strong Responses in Difficult-to-treat Multiple Myeloma
Selinexor in combination with dexamethasone and Pomalyst…
MMRF Launches CureCloud Data Hub to Identify Treatment Targets
Addressing the need for shared, comprehensive data to identify…
Darzalex Combo Extends Survival in Newly Diagnosed Myeloma Patients, Phase 3 Trial Shows
Adding Darzalex (daratumumab) to the standard first-line treatment of…
CT103A CAR T-cell Therapy Leads to Strong Anti-cancer Responses in Relapsed or Refractory Multiple Myeloma Patients, Trial Shows
CT103A, a fully-human anti-B-cell mature antigen (BCMA)…
